Clinical trial
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
NCT02787304 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 24, 2016
- Completion date
- July 27, 2018
- Enrollment
- 197 (actual)
- Sites
- 65
Conditions
As the registry lists them; a condition with its own page is linked.
non-alcoholic steatohepatitis